Actively Recruiting
Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis
Led by Chen Ying · Updated on 2025-05-21
782
Participants Needed
1
Research Sites
96 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study aimed to investigate the effectiveness of anisodamine hydrobromide combined with heparin in the treatment of patients with critical infection, in the hope that the therapy will provide alternatives to the treatment of patients with critical infection.
CONDITIONS
Official Title
Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 18 years
- Diagnosed with sepsis according to the Sepsis-3 criteria
- Patient or legal representative agrees to treatment and signs informed consent form
You will not qualify if you...
- Expected to die within 24 hours after enrollment
- Contraindications to low molecular weight heparin and scopolamine butylbromide
- Having thrombotic diseases requiring treatment with low molecular weight heparin
- Terminal-stage malignancies, severe immunodeficiency, immunosuppression, or severe liver/kidney dysfunction (SOFA score 63 3 points)
- Pregnant or lactating women
- Currently participating in other clinical trials
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Chaoyang Hospital, Capital Medical University
Beijing, China, China, 100020
Actively Recruiting
Research Team
D
Dong Hongmeng
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here